A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Age-related Macular Degeneration

Interventions

DRUG

volociximab

volociximab intravitreal injection